SCHEMBL30749121

SCHEMBL30749121

C1=C(c2cncnc2Nc2ccc(N3CCOCC3)nc2)OCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.44
CYP1A2 P05177 2/20 0.41
MAP4K4 O95819 1/20 0.41
PTK6 Q13882 1/20 0.40
RAB9A P51151 3/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPC1 O15118 2/20 0.38
FGFR2 P21802 1/20 0.38
FGFR3 P22607 1/20 0.38
BTK Q06187 2/20 0.37
STAT3 P40763 1/20 0.37
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748948 0.84 FLT3 (0.43) FLT3CYP1A2PTK6RAB9AMAPT
SCHEMBL31691299 0.76 GAA (0.38) FLT3CYP1A2PTK6MAPTGAA
SCHEMBL30748790 0.71 FLT3 (0.48) FLT3CYP1A2MAP4K4PTK6RAB9A
SCHEMBL4504400 0.66 RAB9A (0.52) CYP1A2RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL1096176 0.66 ADK (0.47) FLT3CYP1A2RAB9AMAPTSMN1; SMN2
SCHEMBL2790485 0.65 MAPT (0.58) CYP1A2RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL16864479 0.65 MAPT (0.54) CYP1A2RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL13034793 0.65 MAPT (0.54) CYP1A2RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL1476927 0.65 MAPKAPK5 (0.50) FLT3CYP1A2MAP4K4PTK6RAB9A
SCHEMBL1094812 0.64 ADK (0.58) CYP1A2RAB9AMAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed